| Literature DB >> 36031674 |
Mohsen Rajabnia1, Shideh Moftakhari Hajimirzaei2, Mohammad Reza Hatamnejad1, Shabnam Shahrokh3, Shaghayegh Baradaran Ghavami4, Maryam Farmani1, Naghmeh Salarieh2, Nastaran Ebrahimi2, Nesa Kazemifard1, Azam Farahanie2, Ghazal Sherkat5, Hamid Asadzadeh Aghdaei1.
Abstract
Obesity, a morbid condition snowballing in the world, may cause many health issues in healthy and ill people. Many disorders are known to be influenced by obesity, mainly in a catastrophic way, including inflammatory bowel disease (IBD). Many studies sought to determine the effects that obesity prompts IBD. Some of them indicate that obesity is associated with poor outcomes. There is no consistency regarding the correlation between obesity and IBDs due to the equivocal nature of obesity and the shortage of extensive and reliable investigations. However, to a worldwide consensus, obesity has a unique disease burden and can cause poor prognosis when it accompanies other ailments. Here, we have reviewed some of the alterations and impacts that obesity may impose on the pathogenesis and clinical management of IBD. Conclusively, inflammatory processes of IBD are reinforced by obesity. Furthermore, as a two-way road, obesity can be caused by IBD. However, autoimmunity in IBD is not found to have a consistent relationship with obesity. Although, medical and surgical treatments of IBD are affected by obesity in terms of their efficacy and outcomes. The most important aspect of obesity that can influence the course of disease management is associated with significant disabilities that obesity may cause rather than a metabolic or molecular rationale.Entities:
Keywords: Adipokines; Adipose tissue; Crohn’s disease; Inflammatory bowel diseases; Obesity; Ulcerative colitis
Year: 2022 PMID: 36031674 DOI: 10.1007/s12026-022-09315-7
Source DB: PubMed Journal: Immunol Res ISSN: 0257-277X Impact factor: 4.505